

A sample article title for the "Cesk Patol" journal

John Nowak¹, Thomas Nowakov^{1,2}, Peter Joseph Smith³

¹ *Department of Pathology, King's College London, London, UK*

² *Department of Pathology, Charles University, Prague, Czech Republic*

³ *Department of Oncology, Institute of Sciences, Stanford CA, USA*

Correspondence address:

Name, Titles

Department, Institution

Mail Address, City, ZIPcode

State, Country

Phone number, Fax number

Email address

Introduction starts without a heading, XXXXXXXXXXX XXXXXX XXXXXXXXXXX XXXXXXXX

XXXXXXXXXXXXXXXXXXXX X X XXXXX XXXXXXXXXXX X XX XXXXXX XXXXXXXXXXXXXXXXXXX XXXXXXXX XX

x. (1) XXXXXXXXXXX XXXXXXX

XXXXXXXXXXXX XXXXXX XXXXXXXXXXX XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXX X X XXXXXX XXXXXXXX X

XX XXXXXX XXXXXXXXXXXXXXXXXXX XXXXXXXX XX X (2,3).

XXXXXXXXXXXX XXXXXX XXXXXXXXXXX XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXX X X XXXXXX XXXXXXXX X

XX XXXXXX XXXXXXXXXXXXXXXXXXX XXXXXXXX XX X.

XXXXXXXXXXXX XXXXXX XXXXXXXXXXX XXXXXXXX (4-7) XXXXXXXXXXXXXXXXXXXXXXX X X XXXXXX

XXXXXXXXXXXX X XX.

MATERIALS AND METHODS

XXXXXXXXXXXX XXXXXX XXXXXXXXXXX XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXX X X XXXXXX XXXXXXXX X

XX

XXXXXXXXXXXX XXXXXX XXXXXXXXXXX XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXX X X XXXXXX XXXXXXXX X

XX XXXXXX XXXXXXXXXXXXXXXXXXX XXXXXXXX XX X (clone A2, LabVision Co.)

XXXXXXXXXXXX XXXXXX XXXXXXXXXX XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXX X X XXXXXX XXXXXXXX X

XX

XXXXXXXXXXXX XXXXXX XXXXXXXXXXX XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXX X X XXXXXX XXXXXXXX X

XX XXXXXX XXXXXXXXXXXXXXXXXXX XXXXXXXX XX X.

RESULTS

Subheading (level 2 - bold)

Subheading (level 3 - bold + italics)

Subheading (level 4 - italics)

XX XXXXXX XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXX XX X (Fig. 1). XXXXXX XXXXXXXXXXXXXXXXXXXX

XXXXXXXXXX XX X (Fig. 2A). XXXXXXXXXXX XXXXXX XXXXXXXXXXX XXXXXXXXXXX

XXXXXXXXXXXXXXXXXXXX X X XXXXX XXXXXXXXXXX X XX

XXXXXXXXXXXXXXXXXXXX X X XXXXX XXXXXXXXXXX X XX (Fig. 2B) XXXXXX XXXXXXXXXXXXXXXXXXXX

XXXXXXXXXX XX X. XXXXXX XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXX XX X (Tab. 1).

In the Table 2 XXXXXXXXXXX XXXXXX XXXXXXXXXXX XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXX X X XXXXX

XXXXXXXXXX X XX XXXXXX XX X.

DISCUSSION**Subheading (level 2 - bold)***Subheading (level 3 - bold + italics)**Subheading (level 4 - italics)*

XXXXXXXXXX (2) XXXXXX XXXXXXXXXXX XXXXXXXXXXX (3,7) XXXXXXXXXXXXXXXXXXXX X X XXXXX

XXXXXXXXXX X XX XXXXXX XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXX XX X. XXXXXXXXXXX XXXXXX

XXXXXXXXXX XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXX X X XXXXX XXXXXXXXXXX X (XX XXXXXX

XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXX XX X.

XXXXXXXXXX XXXXXX XXXXXXXXXXX XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXX (8-10) X X XXXXX

XXXXXXXXXX X XX XXXXXX XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXX (1, 2-4) XX X.

XXXXXXXXXX XXXXXX XXXXXXXXXXX XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXX X X XXXXX XXXXXXXXXXX X.

ACKNOWLEDGEMENTS

Text of Acknowledgements.

REFERENCES

1. **Galizia E, Giorgetti G, Piccinini G, et al.** BRCA1 expression in triple negative sporadic breast cancers. *Anal Quant Cytol Histol* 2010; 32(1): 123-129.
2. **Glinoe D.** Thyroid disease during pregnancy. *In: Braverman LE, Utiger RE,* eds. *Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text* (8th ed). Philadelphia, PA: Lippincott Williams & Wilkins; 2000: 1013–1027.
3. **Stevens A, Lowe J.** Pathology (2nd edn). Mosby: London; 2000: 224–226.
4. **Baselga J, Rothenberg ML, Tabernero J.** TGF- β 1, pSMAD and TGF β -related markers in patients with advanced metastatic cancer. *Proc Natl Acad Sci USA*. In press 2011.
5. xxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx
6. xxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx
7. xxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx
8. xxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx
9. xxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx
10. xxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx

Table 1. Description xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx.

| | n | xx | xx | xxx |
|----------|----------|-----------|-----------|------------|
| A | 3 | 10 | 5 | p < 0.001 |
| B | 4 | 10 | 5 | p < 0.001 |
| C | 5 | 10 | 5 | p < 0.001 |

n, number of patients

Cesk Patol

Table 2. Description xxxxxxxx xxxxxxxx xxxxxxx xxxxxxx.

| | n | xx | xx | xxx |
|----------|----------|-----------|-----------|------------|
| D | 3 | 10 | 5 | p < 0.001 |
| E | 4 | 10 | 5 | p < 0.001 |
| F | 5 | 10 | 5 | p < 0.001 |

n, number of patients

Cesk Patol

FIGURE LEGEND

Fig. 1. Figure legend text. XXXXXXXXXXX XXXXXX XXXXXXXXXXX XXXXXXXX

XXXXXXXXXXXXXXXXXXXX X X XXXXXX XXXXXXXXXXX X XX XXXXXX XXXXXXXXXXXXXXXXXXX XXXXXXXXXXX XX

X XXXXXXXXXXX X XX XXXXXX.

Fig. 2. Figure legend text. XXXXXXXXXXX XXXXXX XXXXXXXXXXX XXXXXXXX

XXXXXXXXXXXXXXXXXXXX X X XXXXXX XXXXXXXXXXX X XX XXXXXX XXXXXXXXXXXXXXXXXXX XXXXXXXXXXX XX

X XXXXXXXXXXX X XX XXXXXX.

Cesk Patol